Christopher J Ryerson, Mas

List of Publications by Year
in descending order

166 papers	18,107 citations	53751 45 h-index	14197 128 g-index
168 all docs	168 docs citations	168 times ranked	12489 citing authors

#	Article	IF	Citations
1	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	2.5	3,134
2	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
3	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
4	A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 2012, 156, 684.	2.0	918
5	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic. Chest, 2020, 158, 106-116.	0.4	832
6	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	2.5	780
7	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	5.2	739
8	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology, 2020, 296, 172-180.	3.6	721
9	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
10	Predicting Survival Across Chronic Interstitial Lung Disease. Chest, 2014, 145, 723-728.	0.4	366
11	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respiratory Medicine,the, 2020, 8, 726-737.	5.2	279
12	Clinical Features and Outcomes in Combined Pulmonary Fibrosis and Emphysema in Idiopathic Pulmonary Fibrosis. Chest, 2013, 144, 234-240.	0.4	239
13	Prevalence and prognosis of unclassifiable interstitial lung disease. European Respiratory Journal, 2013, 42, 750-757.	3.1	238
14	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2021, 222, 107798.		216
15	Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease. Chest, 2014, 146, 422-436.	0.4	193
16	Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 151, 619-625.	0.4	177
17	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	2.5	174
18	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	2.5	166

#	Article	IF	Citations
19	Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. European Respiratory Journal, 2015, 46, 512-520.	3.1	164
20	Radiographic Fibrosis Score Predicts Survival in Hypersensitivity Pneumonitis. Chest, 2013, 144, 586-592.	0.4	158
21	Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease: A Systematic Review and Meta-analysis. Annals of the American Thoracic Society, 2016, 13, 1828-1838.	1.5	158
22	Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: A prospective cohort study. Respiratory Medicine, 2014, 108, 203-210.	1.3	156
23	Patient-reported outcome measures after COVID-19: a prospective cohort study. European Respiratory Journal, 2020, 56, 2003276.	3.1	148
24	A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax, 2021, 76, 402-404.	2.7	146
25	Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology, 2011, 16, 969-975.	1.3	137
26	Frailty and postoperative outcomes in patients undergoing surgery for degenerative spine disease. Spine Journal, 2016, 16, 1315-1323.	0.6	133
27	Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e121-e141.	2.5	133
28	Depression and Functional Status Are Strongly Associated With Dyspnea in Interstitial Lung Disease. Chest, 2011, 139, 609-616.	0.4	120
29	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.5	120
30	Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. Respiratory Physiology and Neurobiology, 2021, 288, 103644.	0.7	111
31	Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 218-225.	2.5	98
32	Progression of fibrosing interstitial lung disease. Respiratory Research, 2020, 21, 32.	1.4	94
33	Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology, 2012, 17, 525-532.	1.3	86
34	Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respiratory Medicine, 2013, 107, 249-255.	1.3	84
35	YouTube Videos as a Source of Misinformation on Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 572-579.	1.5	82
36	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75

#	Article	IF	Citations
37	Hypersensitivity pneumonitis. Nature Reviews Disease Primers, 2020, 6, 65.	18.1	75
38	Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2018, 15, 854-863.	1.5	74
39	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800663.	3.1	73
40	Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respiratory Research, 2010, 11, 12.	1.4	69
41	Dyspnea in Idiopathic Pulmonary Fibrosis: AÂSystematic Review. Journal of Pain and Symptom Management, 2012, 43, 771-782.	0.6	63
42	Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. Respirology, 2018, 23, 392-398.	1.3	63
43	Unclassifiable interstitial lung disease: A review. Respirology, 2016, 21, 51-56.	1.3	60
44	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
45	Update on the diagnosis and classification of ILD. Current Opinion in Pulmonary Medicine, 2013, 19, 453-459.	1.2	58
46	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078.	0.4	57
47	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respiratory Medicine,the, 2021, 9, 1065-1076.	5.2	55
48	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. Chest, 2021, 159, 1107-1125.	0.4	53
49	Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. European Respiratory Journal, 2021, 58, 2004188.	3.1	47
50	A Primer on Interstitial Lung Disease and Thoracic Radiation. Journal of Thoracic Oncology, 2020, 15, 902-913.	0.5	46
51	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	0.8	45
52	Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease. European Respiratory Journal, 2017, 49, 1602494.	3.1	45
53	Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 1268-1275.	0.4	44
54	Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 531-549.	3.6	43

#	Article	IF	Citations
55	Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. European Respiratory Journal, 2021, 57, 2004455.	3.1	42
56	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2018, 96, 314-322.	1.2	41
57	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	2.5	41
58	Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease. Respirology, 2017, 22, 728-734.	1.3	40
59	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society, 2016, 13, 1640-1647.	1.5	37
60	Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulmonary Medicine, 2019, 19, 192.	0.8	37
61	Managing comorbidities in idiopathic pulmonary fibrosis. International Journal of General Medicine, 2015, 8, 309.	0.8	35
62	Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease. Annals of the American Thoracic Society, 2019, 16, 455-462.	1.5	35
63	Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study. Respiratory Research, 2019, 20, 56.	1.4	34
64	The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?. European Respiratory Journal, 2018, 51, 1702420.	3.1	33
65	Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1700168.	3.1	32
66	Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. Modern Pathology, 2020, 33, 616-625.	2.9	32
67	Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. Annals of the American Thoracic Society, 2017, 14, 1373-1377.	1.5	30
68	Acute exacerbations complicating interstitial lung disease. Current Opinion in Pulmonary Medicine, 2014, 20, 436-441.	1.2	29
69	Cough is less common and less severe in systemic sclerosisâ€associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology, 2017, 22, 1592-1597.	1.3	28
70	Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. European Respiratory Journal, 2018, 51, 1701726.	3.1	28
71	Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes. European Respiratory Journal, 2020, 55, 1900647.	3.1	28
72	Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax, 2021, 76, 37-43.	2.7	28

#	Article	IF	Citations
73	Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. Respiratory Medicine, 2017, 129, 1-7.	1.3	26
74	Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 1327-1329.	1.5	26
75	A global registry for idiopathic pulmonary fibrosis: the time is now. European Respiratory Journal, 2014, 44, 273-276.	3.1	25
76	Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 459-467.	2.5	25
77	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1320-1329.	0.4	25
78	Interstitial lung disease and obstructive sleep apnea. Sleep Medicine Reviews, 2021, 58, 101442.	3.8	22
79	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Research, 2019, 5, 00127-2018.	1.1	21
80	Update in Interstitial Lung Disease 2020. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1343-1352.	2.5	21
81	Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax, 2022, 77, 589-595.	2.7	21
82	Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respiratory Medicine Journal, 2020, 14, 22-31.	1.3	21
83	Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial. BMC Cancer, 2019, 19, 1206.	1.1	20
84	Minimal Important Difference for Physical Activity and Validity of the International Physical Activity Questionnaire in Interstitial Lung Disease. Annals of the American Thoracic Society, 2019, 16, 107-115.	1.5	20
85	Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. Chest, 2021, 160, 994-1005.	0.4	20
86	Oesophageal diameter is associated with severity but not progression of systemic sclerosisâ€associated interstitial lung disease. Respirology, 2018, 23, 921-926.	1.3	19
87	Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies. Expert Review of Respiratory Medicine, 2020, 14, 405-414.	1.0	19
88	Association of Computed Tomography Densitometry with Disease Severity, Functional Decline, and Survival in Systemic Sclerosis-associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 813-820.	1.5	19
89	A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. European Respiratory Journal, 2021, 58, 2100276.	3.1	19
90	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19

#	Article	IF	Citations
91	Management of dyspnea in interstitial lung disease. Current Opinion in Supportive and Palliative Care, 2010, 4, 69-75.	0.5	18
92	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322.	1.4	18
93	Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study. Respirology, 2021, 26, 683-689.	1.3	17
94	Changes in pulmonary function and patient-reported outcomes during COVID-19 recovery: a longitudinal, prospective cohort study. ERJ Open Research, 2021, 7, 00243-2021.	1.1	17
95	Successful lung transplantation in an HIV seropositive patient with desquamative interstitial pneumonia: a case report. BMC Pulmonary Medicine, 2018, 18, 162.	0.8	16
96	Air Pollution and Interstitial Lung Diseases: Defining Epigenomic Effects. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1217-1224.	2.5	16
97	The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF). EBioMedicine, 2021, 66, 103325.	2.7	16
98	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27.	1.5	16
99	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.2	15
100	Unclassifiable interstitial lung disease. Current Opinion in Pulmonary Medicine, 2018, 24, 461-468.	1.2	15
101	Exercise Pathophysiology in Interstitial Lung Disease. Clinics in Chest Medicine, 2019, 40, 405-420.	0.8	14
102	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895.	0.4	14
103	Pectoralis muscle area and its association with indices of disease severity in interstitial lung disease. Respiratory Medicine, 2021, 186, 106539.	1.3	14
104	The Many Faces of Hypersensitivity Pneumonitis. Chest, 2017, 152, 458-460.	0.4	13
105	Impact of Psychological Deficits and Pain on Physical Activity of Patients with Interstitial Lung Disease. Lung, 2019, 197, 415-425.	1.4	13
106	Cardiopulmonary Exercise Testing in Patients With Interstitial Lung Disease. Frontiers in Physiology, 2020, 11, 832.	1.3	12
107	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644.	1.3	12
108	Hot off the breath: a big step forward for idiopathic pulmonary fibrosis. Thorax, 2014, 69, 791-792.	2.7	11

#	Article	IF	Citations
109	Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. European Respiratory Journal, 2019, 53, 1802182.	3.1	11
110	Frailty in patients with interstitial lung disease. Current Opinion in Pulmonary Medicine, 2020, 26, 449-456.	1.2	11
111	Determining Respiratory Impairment in Connective Tissue Diseaseâ€“Associated Interstitial Lung Disease. Rheumatic Disease Clinics of North America, 2015, 41, 213-223.	0.8	10
112	The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2015, 109, 1058-1062.	1.3	9
113	Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1901188.	3.1	9
114	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.2	8
115	Quality indicators for pulmonary rehabilitation programs in Canada: A Canadian Thoracic Society expert working group report. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 199-209.	0.2	8
116	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 797-808.	1.9	8
117	Unclassifiable interstitial lung disease: an unresolved diagnostic dilemma. Respirology Case Reports, 2015, 3, 85-88.	0.3	7
118	Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence. European Respiratory Review, 2017, 26, 170033.	3.0	7
119	Qualitative dimensions of exertional dyspnea in fibrotic interstitial lung disease. Respiratory Physiology and Neurobiology, 2019, 266, 1-8.	0.7	7
120	Methodologic Guidance and Expectations for the Development and Reporting of Prediction Models and Causal Inference Studies. Annals of the American Thoracic Society, 2020, 17, 679-682.	1.5	7
121	Nocturnal hypoxaemia in interstitial lung disease: a systematic review. Thorax, 2021, 76, 1200-1208.	2.7	7
122	Social Media Content of Idiopathic Pulmonary Fibrosis Groups and Pages on Facebook: Cross-sectional Analysis. JMIR Public Health and Surveillance, 2021, 7, e24199.	1.2	7
123	Pulmonary Apical Cap as a Potential Risk Factor for Pleuroparenchymal Fibroelastosis. Chest, 2021, 159, e365-e370.	0.4	7
124	Canadian Thoracic Society position statement on rehabilitation for COVID-19 and implications for pulmonary rehabilitation. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 9-13.	0.2	7
125	Lumpers versus splitters: What to do with suspected idiopathic pulmonary fibrosis?. Respirology, 2019, 24, 300-301.	1.3	6
126	Diagnostic Classification of Interstitial Lung Disease in Clinical Practice. Clinics in Chest Medicine, 2021, 42, 251-261.	0.8	6

#	Article	IF	Citations
127	Effects of Traffic-Related Air Pollution on Exercise Endurance, Dyspnea, and Cardiorespiratory Responses in Health and COPD. Chest, 2022, 161, 662-675.	0.4	6
128	Creating a provincial post <scp>COVID</scp>â€19 interdisciplinary clinical care network as a learning health system during the pandemic: Integrating clinical care and research. Learning Health Systems, 2023, 7, .	1.1	6
129	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	1.4	5
130	Making Sense of Bronchoalveolar Lavage Lymphocytosis in Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1382-1383.	1.5	5
131	Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. Respiratory Medicine, 2022, 195, 106792.	1.3	5
132	A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies. BMC Pulmonary Medicine, 2022, 22, 148.	0.8	5
133	YouTube-videos for patient education in lymphangioleiomyomatosis?. Respiratory Research, 2022, 23, 103.	1.4	5
134	Oxygen Prescription in Interstitial Lung Disease: 2.5 Billion Years in the Making. Annals of the American Thoracic Society, 2017, 14, 1755-1756.	1.5	4
135	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society, 2021, 18, 1661-1668.	1.5	4
136	The opportunities and challenges of social media in interstitial lung disease: a viewpoint. Respiratory Research, 2021, 22, 247.	1.4	4
137	Fibroblast Foci and Patchy Fibrosis Do Not Separate Usual Interstitial Pneumonia From Fibrotic Hypersensitivity Pneumonitis in Transbronchial Cryobiopsies. Archives of Pathology and Laboratory Medicine, 2021, 145, 1325-1326.	1.2	4
138	POINT: Should Surgical Lung Biopsy Still Be Performed for Interstitial Lung Disease Evaluation? Yes. Chest, 2021, 160, 2007-2011.	0.4	4
139	Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1594-1597.	0.4	4
140	Clinical relevance of rheumatoid factor and antiâ€citrullinated peptides in fibrotic interstitial lung disease. Respirology, 0, , .	1.3	4
141	Combined pulmonary fibrosis and emphysema. Current Respiratory Care Reports, 2013, 2, 254-259.	0.6	3
142	Diagnostic criteria for idiopathic pulmonary fibrosis â€“ Authorsâ€™ reply. Lancet Respiratory Medicine,the, 2018, 6, e7.	5.2	3
143	Supplemental oxygen for the management of dyspnea in interstitial lung disease. Current Opinion in Supportive and Palliative Care, 2019, 13, 174-178.	0.5	3
144	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 147-155.	0.2	3

#	Article	IF	Citations
145	An Updated Assessment of Online Information on Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1421-1423.	1.5	3
146	Endobronchial Optical Coherence Tomography for the Diagnosis of Fibrotic Interstitial Lung Disease: A Light at the End of the Tunnel?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1122-1124.	2.5	3
147	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	1.3	3
148	Frailty and chronic respiratory disease: the need for a multidisciplinary care model. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021031.	0.2	3
149	Systematic review of content and quality of idiopathic pulmonary fibrosis review articles. ERJ Open Research, 2018, 4, 00156-2018.	1.1	2
150	Nocturnal hypoxaemia in interstitial lung disease: An easy target to treat?. Respirology, 2019, 24, 930-932.	1.3	2
151	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 226-228.	0.2	2
152	A closer look at the multidisciplinary interstitial lung disease clinic: Who, what and how. Respirology, 2021, 26, 12-13.	1.3	2
153	Transbronchial lung cryobiopsy in ILD: the data we've been waiting for. Lancet Respiratory Medicine,the, 2020, 8, 129-130.	5.2	1
154	Characterization and determinants of sleep measured by self-report and wrist actigraphy in patients with interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 88-96.	0.2	1
155	Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?. European Respiratory Journal, 2020, 55, 2000894.	3.1	1
156	Real-world appropriateness of imaging severity thresholds in interstitial lung disease clinical trials. Lancet Respiratory Medicine,the, 2020, 8, e7.	5.2	1
157	Reply: Quantitative Computed Tomography in Systemic Sclerosisâ€“Interstitial Lung Disease: Are We Ready to Go beyond Standard Assessment?. Annals of the American Thoracic Society, 2021, 18, 184-184.	1.5	1
158	Costs of oxygen therapy for interstitial lung disease and chronic obstructive pulmonary disease: A retrospective study from a universal healthcare system. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 351-358.	0.2	1
159	P005 <break /> Rate of progression in short-term and long-term survivors with systemic sclerosis-associated interstitial lung disease. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.2	0
160	Physical activity measurement accuracy in advanced chronic lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 9-18.	0.2	0
161	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 257-258.	0.2	0
162	Update in the diagnostic approach to fibrotic interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 155-159.	0.2	0

#	Article	IF	Citations
163	Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 25-30.	0.2	0
164	Moving From Multidisciplinary Phenotyping to Biological Classification of Fibrotic Interstitial Lung Disease. Chest, 2020, 158, 1814-1815.	0.4	0
165	Interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, S21-S24.	0.2	0
166	Rebuttal From Dr Ryerson. Chest, 2021, 160, 2014-2015.	0.4	0